324 related articles for article (PubMed ID: 27272086)
21. Efficacy and safety of topical brimonidine in dermatology: A review article.
Saki N; Amani M; Nezhad NZ; Shahpar A; Shafiei M; Hosseini SA; Ahramiyanpour N
Dermatol Ther; 2022 Nov; 35(11):e15819. PubMed ID: 36097378
[TBL] [Abstract][Full Text] [Related]
22. Brimonidine displays anti-inflammatory properties in the skin through the modulation of the vascular barrier function.
Bertino B; Blanchet-Réthoré S; Thibaut de Ménonville S; Reynier P; Méhul B; Bogouch A; Gamboa B; Dugaret AS; Zugaj D; Petit L; Roquet M; Piwnica D; Vial E; Bourdès V; Voegel JJ; Nonne C
Exp Dermatol; 2018 Dec; 27(12):1378-1387. PubMed ID: 30290018
[TBL] [Abstract][Full Text] [Related]
23. Optimizing the use of topical brimonidine in rosacea management: panel recommendations.
Tanghetti EA; Jackson JM; Belasco KT; Friedrichs A; Hougier F; Johnson SM; Kerdel FA; Palceski D; Hong HC; Hinek A; Cadena MJ
J Drugs Dermatol; 2015 Jan; 14(1):33-40. PubMed ID: 25607906
[TBL] [Abstract][Full Text] [Related]
24. Brimonidine tartrate for the treatment of facial flushing and erythema in rosacea.
Tong LX; Moore AY
Expert Rev Clin Pharmacol; 2014 Sep; 7(5):567-77. PubMed ID: 25091290
[TBL] [Abstract][Full Text] [Related]
25. Difference in vasoconstrictors: oxymetazoline vs. brimonidine.
Okwundu N; Cline A; Feldman SR
J Dermatolog Treat; 2021 Mar; 32(2):137-143. PubMed ID: 31294643
[TBL] [Abstract][Full Text] [Related]
26. Erythema of Rosacea: Validation of Patient's Self-Assessment Grading Scale.
Tan J; Leoni M
J Drugs Dermatol; 2015 Aug; 14(8):841-4. PubMed ID: 26267728
[TBL] [Abstract][Full Text] [Related]
27. Multidisciplinary Consideration of Potential Pathophysiologic Mechanisms of Paradoxical Erythema with Topical Brimonidine Therapy.
Docherty JR; Steinhoff M; Lorton D; Detmar M; Schäfer G; Holmes A; Di Nardo A
Adv Ther; 2016 Nov; 33(11):1885-1895. PubMed ID: 27562835
[TBL] [Abstract][Full Text] [Related]
28. Sensitization to and allergic contact dermatitis caused by Mirvaso(®) (brimonidine tartrate) for treatment of rosacea - 2 cases.
Bangsgaard N; Fischer LA; Zachariae C
Contact Dermatitis; 2016 Jun; 74(6):378-9. PubMed ID: 27133629
[No Abstract] [Full Text] [Related]
29. Medical Management of Facial Redness in Rosacea.
Cline A; McGregor SP; Feldman SR
Dermatol Clin; 2018 Apr; 36(2):151-159. PubMed ID: 29499798
[TBL] [Abstract][Full Text] [Related]
30. Brimonidine gel for the treatment of recalcitrant facial erythema in diseases other than rosacea: a novel tool for clinicians.
Del Barrio-Díaz P; Moll-Manzur C; Vera-Kellet C
J Eur Acad Dermatol Venereol; 2017 Jan; 31(1):e32-e33. PubMed ID: 26990727
[No Abstract] [Full Text] [Related]
31. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial.
Elewski BE; Fleischer AB; Pariser DM
Arch Dermatol; 2003 Nov; 139(11):1444-50. PubMed ID: 14623704
[TBL] [Abstract][Full Text] [Related]
32. [Brimonidine (Mirvaso), dermal use].
Van Genechten D
J Pharm Belg; 2015 Jun; (2):45-6. PubMed ID: 26466509
[No Abstract] [Full Text] [Related]
33. Inhibition of mast cell infiltration in an LL-37-induced rosacea mouse model using topical brimonidine tartrate 0.33% gel.
Kim M; Kim J; Jeong SW; Jo H; Woo YR; Park HJ
Exp Dermatol; 2017 Nov; 26(11):1143-1145. PubMed ID: 28500634
[TBL] [Abstract][Full Text] [Related]
34. Primum non nocere; the importance of evaluating the effect of treatment and considering side effects.
Sukakul T; Dahlin J; Svedman C
Contact Dermatitis; 2021 Feb; 84(2):121-122. PubMed ID: 32713000
[No Abstract] [Full Text] [Related]
35. Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the Second REVEAL Trial.
Baumann L; Goldberg DJ; Stein Gold L; Tanghetti EA; Lain E; Kaufman J; Weng E; Berk DR; Ahluwalia G
J Drugs Dermatol; 2018 Mar; 17(3):290-298. PubMed ID: 29537447
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: Findings from the 52-week open label REVEAL trial.
Draelos ZD; Gold MH; Weiss RA; Baumann L; Grekin SK; Robinson DM; Kempers SE; Alvandi N; Weng E; Berk DR; Ahluwalia G
J Am Acad Dermatol; 2018 Jun; 78(6):1156-1163. PubMed ID: 29409914
[TBL] [Abstract][Full Text] [Related]
37. Carvedilol ameliorates persistent erythema of erythematotelangiectatic rosacea by regulating the status of anxiety/depression.
Li J; Tang JY; Fu J; Zhang MW; Wan M; Chen DW; Chen QQ; Li X; Song GJ; Ni RR; Song ZQ
J Dermatol; 2022 Nov; 49(11):1139-1147. PubMed ID: 35904063
[TBL] [Abstract][Full Text] [Related]
38. Treatment of facial erythema in patients with rosacea with topical brimonidine tartrate: correlation of patient satisfaction with standard clinical endpoints of improvement of facial erythema.
Fowler J; Tan J; Jackson JM; Meadows K; Jones T; Jarratt M; Leoni M;
J Eur Acad Dermatol Venereol; 2015 Mar; 29(3):474-81. PubMed ID: 25074756
[TBL] [Abstract][Full Text] [Related]
39. Oxymetazoline hydrochloride cream for facial erythema associated with rosacea.
Patel NU; Shukla S; Zaki J; Feldman SR
Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1049-1054. PubMed ID: 28837365
[TBL] [Abstract][Full Text] [Related]
40. Spotlight on brimonidine topical gel 0.33% for facial erythema of rosacea: safety, efficacy, and patient acceptability.
Anderson MS; Nadkarni A; Cardwell LA; Alinia H; Feldman SR
Patient Prefer Adherence; 2017; 11():1143-1150. PubMed ID: 28740369
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
